The AML-IRF7−/− mice exhibited higher levels of PB, SP and bone marrow leukemia cells since day 10 (Fig. 1B) and had shorter survival times than AML-WT mice (Fig. 1C). This evidence concerns the gene IRF7 and acute myeloid leukemia.